SECTION 1. IDENTIFICATION

Product name : Furosemide Injection Formulation

Manufacturer or supplier's details
Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Specific target organ toxicity - repeated exposure : Category 1 (Kidney, Liver)

GHS label elements
Hazard pictograms :

Signal Word : Danger
Hazard Statements : H372 Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Precautionary Statements :
Prevention:
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:
P314 Get medical attention if you feel unwell.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture
Components
SAFETY DATA SHEET

Furosemide Injection Formulation

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>54-31-9</td>
<td>&gt;= 5 - &lt; 10</td>
</tr>
</tbody>
</table>

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes damage to organs through prolonged or repeated exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire fighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Nitrogen oxides (NOx)
Carbon oxides
Sulfur oxides
Chlorine compounds

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES
SAFETY DATA SHEET

Furosemide Injection Formulation

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
Use only with adequate ventilation.

Advice on safe handling:
Do not breathe mist or vapors.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
Keep in properly labeled containers.
Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters
Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis
--- | --- | --- | --- | ---
Furosemide | 54-31-9 | TWA | 200 µg/m³ | Internal

**Engineering measures**: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

**Personal protective equipment**

**Respiratory protection**: General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection Material**: Chemical-resistant gloves

**Eye protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**: Work uniform or laboratory coat.

**Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

**Appearance**: Aqueous solution

**Color**: yellow
Furosemide Injection Formulation

SAFETY DATA SHEET

Odor: No data available
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: No data available
Evaporation rate: No data available
Flammability (solid, gas): Not applicable
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapor pressure: No data available
Relative vapor density: No data available
Relative density: No data available
Density: No data available
Solubility(ies)
  Water solubility: No data available
Partition coefficient: n-octanol/water
  Autoignition temperature: No data available
  Decomposition temperature: No data available
Viscosity
  Viscosity, kinematic: No data available
Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Particle size: Not applicable

SECTION 10. STABILITY AND REACTIVITY
SAFETY DATA SHEET

Furosemide Injection Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4</td>
<td>10/10/2020</td>
<td>632214-00011</td>
<td>03/23/2020</td>
<td>05/03/2016</td>
</tr>
</tbody>
</table>

- **Reactivity**: Not classified as a reactivity hazard.
- **Chemical stability**: Stable under normal conditions.
- **Possibility of hazardous reactions**: Can react with strong oxidizing agents.
- **Conditions to avoid**: None known.
- **Incompatible materials**: Oxidizing agents
- **Hazardous decomposition products**: No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

**Information on likely routes of exposure**

- **Inhalation**
- **Skin contact**
- **Ingestion**
- **Eye contact**

**Acute toxicity**

Not classified based on available information.

**Product**

**Acute oral toxicity**

- Acute toxicity estimate: > 5,000 mg/kg
- Method: Calculation method

**Components**

**Furosemide**

**Acute oral toxicity**

- LD50 (Rat): 2,600 mg/kg
- LD50 (Dog): 2,000 mg/kg
- LD50 (Rabbit): 800 mg/kg

**Acute toxicity (other routes of administration)**

- LD0 (Humans): 6 - 29 mg/kg
- Application Route: Intravenous

**Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitization**

**Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Germ cell mutagenicity**

Not classified based on available information.
Components:

Furosemide:

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Test system: mouse lymphoma cells
  Result: positive
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  Test system: mammalian liver cells
  Result: negative
- Test Type: Chromosome aberration test in vitro
  Test system: Chinese hamster ovary cells
  Result: positive
- Test Type: In vitro sister chromatid exchange assay in mammalian cells
  Test system: Chinese hamster cells
  Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Mouse
  Application Route: Ingestion
  Result: negative
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  Species: Chinese hamster
  Application Route: Ingestion
  Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Furosemide:

Species: Rat
Application Route: Ingestion
Exposure time: 104 weeks
LOAEL: 16 mg/kg body weight
Result: equivocal

Species: Mouse
Application Route: Ingestion
Exposure time: 2 Years
LOAEL: 91 mg/kg body weight
Result: positive

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is
identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Not classified based on available information.

Components:

Furosemide:
Effects on fertility:
Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
General Toxicity Parent: NOAEL: 90 mg/kg body weight
Result: No effects on reproduction parameters.

Test Type: One-generation reproduction toxicity study
Species: Mouse
Application Route: Ingestion
General Toxicity Parent: NOAEL: 200 mg/kg body weight
Result: No effects on reproduction parameters.

Effects on fetal development:
Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 50 mg/kg body weight
Developmental Toxicity: NOAEL: 300 mg/kg body weight
Result: No embryotoxic effects., No teratogenic effects.

Test Type: Fertility/early embryonic development
Species: Mouse
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 25 mg/kg body weight
Result: Maternal toxicity observed., Fetal effects.

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight
Developmental Toxicity: LOAEL: 12.5 mg/kg body weight
Result: Maternal toxicity observed., Reduced number of viable fetuses.

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 15 mg/kg body weight
Result: Maternal toxicity observed., No effects on fetal development.
STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Components:

Furosemide:
Routes of exposure : Ingestion
Target Organs : Kidney
Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

Repeated dose toxicity

Components:

Furosemide:
Species : Dog
NOAEL : 4 mg/kg
LOAEL : 8 mg/kg
Application Route : Ingestion
Exposure time : 12 Months
Target Organs : Kidney
Symptoms : Blood disorders
Remarks : Significant toxicity observed in testing

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Furosemide:
Inhalation : Remarks: May be harmful if inhaled.
Skin contact : Remarks: May irritate skin.
Eye contact : Remarks: May cause eye irritation.
Ingestion : Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Furosemide:
Toxicity to fish : LC50: 500 mg/l
Exposure time: 96 h
Persistence and degradability
No data available

Bioaccumulative potential

Components:
Furosemide:
Partition coefficient: n-octanol/water: log Pow: 2.03

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
49 CFR
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.
SAFETY DATA SHEET

Furosemide Injection Formulation

Version: 4.4
Revision Date: 10/10/2020
SDS Number: 632214-00011
Date of last issue: 03/23/2020
Date of first issue: 05/03/2016

SARA 311/312 Hazards: Specific target organ toxicity (single or repeated exposure)

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know
Water 7732-18-5
Furosemide 54-31-9

The ingredients of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

SECTION 16. OTHER INFORMATION

Further information
NFPA 704:

HMIS® IV:

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "\"" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with...
SAFETY DATA SHEET

Furosemide Injection Formulation

Version 4.4 | Revision Date: 10/10/2020 | SDS Number: 632214-00011 | Date of last issue: 03/23/2020

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 10/10/2020

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8